Your browser doesn't support javascript.
loading
Chronic orexin-A (hypocretin-1) treatment of type 2 diabetic rats improves glucose control and beta-cell functions.
Kaczmarek, P; Skrzypski, M; Pruszynska-Oszmalek, E; Sassek, M; Kolodziejski, P A; Billert, M; Szczepankiewicz, D; Wojciechowicz, T; Maechler, P; Nowak, K W; Strowski, M Z.
Afiliación
  • Kaczmarek P; Department of Animal Physiology and Biochemistry, Poznan University of Life Sciences, Poznan, Poland.
  • Skrzypski M; Department of Animal Physiology and Biochemistry, Poznan University of Life Sciences, Poznan, Poland.
  • Pruszynska-Oszmalek E; Department of Animal Physiology and Biochemistry, Poznan University of Life Sciences, Poznan, Poland.
  • Sassek M; Department of Animal Physiology and Biochemistry, Poznan University of Life Sciences, Poznan, Poland.
  • Kolodziejski PA; Department of Animal Physiology and Biochemistry, Poznan University of Life Sciences, Poznan, Poland.
  • Billert M; Department of Animal Physiology and Biochemistry, Poznan University of Life Sciences, Poznan, Poland.
  • Szczepankiewicz D; Department of Animal Physiology and Biochemistry, Poznan University of Life Sciences, Poznan, Poland.
  • Wojciechowicz T; Department of Animal Physiology and Biochemistry, Poznan University of Life Sciences, Poznan, Poland.
  • Maechler P; Department of Cell Physiology and Metabolism, University of Geneva Medical Center, Geneva, Switzerland.
  • Nowak KW; Department of Animal Physiology and Biochemistry, Poznan University of Life Sciences, Poznan, Poland.
  • Strowski MZ; Department of Hepatology and Gastroenterology and the Interdisciplinary Centre of Metabolism: Endocrinology, Diabetes and Metabolism, Charite-University Medicine Berlin, Berlin, Germany. strowski@park-klinik.com.
J Physiol Pharmacol ; 68(5): 669-681, 2017 Oct.
Article en En | MEDLINE | ID: mdl-29375041
ABSTRACT
Orexin regulates food intake and energy expenditure. Here, we test the ability of orexin-A (OXA, hypocretin-1) at improving metabolic control in type 2 diabetic animals and elaborate potential mechanisms of action. Rats with experimentally induced type 2 diabetes by a combination of streptozotocin injection and high-fat diet feeding were chronically infused with OXA. In vitro experiments were conducted on isolated pancreatic islets, primary adipocytes and insulin secreting INS-1E cells. OXA improved glucose control, enhanced insulin sensitivity and attenuated pancreatic ß-cell loss in type 2 diabetic rats. Ex vivo, apoptotic death of pancreatic islets isolated from OXA-treated type 2 diabetic animals as well as the impairment of glucose-stimulated insulin secretion were attenuated, as compared to islets derived from vehicle-treated rats. OXA reduced plasma tumor necrosis factor-α (TNF-α) and non-esterified fatty acids (NEFA) levels in type 2 diabetic rats. OXA decreased palmitate- and TNF-α-induced apoptosis of INS-1E cells. OXA improves glucose control by enhancing insulin sensitivity and protecting ß-cells from apoptotic cell death in type 2 diabetic animals.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glucemia / Diabetes Mellitus Experimental / Diabetes Mellitus Tipo 2 / Células Secretoras de Insulina / Orexinas Límite: Animals Idioma: En Revista: J Physiol Pharmacol Asunto de la revista: FARMACOLOGIA / FISIOLOGIA Año: 2017 Tipo del documento: Article País de afiliación: Polonia
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glucemia / Diabetes Mellitus Experimental / Diabetes Mellitus Tipo 2 / Células Secretoras de Insulina / Orexinas Límite: Animals Idioma: En Revista: J Physiol Pharmacol Asunto de la revista: FARMACOLOGIA / FISIOLOGIA Año: 2017 Tipo del documento: Article País de afiliación: Polonia